Oncology and Carcinogenesis articles for United Kingdom (UK)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 483

Article ‘Count’ for Oncology and Carcinogenesis.

Journal Count Share
1 1.00
Multivalent DNA Origami Enables Single-Molecule Dissection of Integrin αvβ6–Receptor Tyrosine Kinase Crosstalk in Cancer Biology 1.00
2 0.76
Positioning and reversible suppression of CCR7+ dendritic cells in perivascular tumor niches shape cancer immunity 0.02
Matrix stiffness shapes transcriptional profiles and drug responses of pancreatic cancer cells 0.74
2 0.77
Shaping Ti3C2 MXene Nanospheres for Precision Near-Infrared Photothermal Therapy 0.05
Precise Quantification of Angiogenesis in 3D Biomaterials Using in Vitro CAM Models: Enhancing 3Rs in Research and Minimizing in Vivo Dependency 0.72
2 1.02
Bi-allelic variants in the non-protein-coding minor spliceosome components RNU6ATAC and RNU4ATAC cause syndromic monogenic autoimmune diabetes 1.00
Bi-allelic loss-of-function variants in JKAMP cause a neurodevelopmental syndrome associated with dysregulation of GPR37 trafficking 0.02
1 1.00
Expanded detection of early fibrotic phenotypes using lobar traction bronchiolectasis in lung cancer screening 1.00
3 1.50
Sensitive Detection and Identification Method of Erythrocyte-like Cells upon Doxorubicin Induced Differentiation with Vibrational Techniques 0.42
A Novel Spectral Barcoding and Classification Approach for Complex Biological Samples Using Multiexcitation Raman Spectroscopy (MX-Raman) 1.00
One-Drop Serum Screening Test to Monitor Tissue Iron Accumulation 0.08
3 1.25
Naphthalimide-Based Type-I Nano-Photosensitizers for Enhanced Antitumor Photodynamic Therapy: H2S Synergistically Regulates PeT and Self-Assembly 0.04
Fragment‐Based Drug Discovery of Novel High‐affinity, Selective, and Anti‐inflammatory Inhibitors of the Keap1‐Nrf2 Protein‐Protein Interaction 0.21
The Iron–Sulfur Cluster of Bacterioferritin‐Associated Ferredoxin (Bfd): a “Biological Fuse” that Prevents Oxidative Damage to Cells? 1.00
1 0.14
Antithrombotic Therapy Discontinuation, Bleeding, and Thromboembolic Events in Patients With Cancer During the Last Phase of Life: Insights From Primary Care Records 0.14
5 0.49
Robotic Pancreatoduodenectomy Carries Greater Risk of Morbidity after Conversion than Laparoscopy: A Propensity Score-Matched Analysis in the E-MIPS Registry. 0.07
The International Study Group for Pancreatic Surgery (ISGPS) Definition and Classification of Postpancreatectomy Mortality. 0.11
Accuracy of Histology and Malignancy Grade between Preoperative Biopsy and Surgical Specimens in Primary Retroperitoneal Sarcoma. A Study from the Prospective Retroperitoneal Sarcoma Registry (Resar). 0.16
Grim Age, Grim Prognosis: Epigenetic Aging Predicts Pancreatic Surgery Risk. 0.04
Recommendations on Perihilar Cholangiocarcinoma. The Milan Jury-Based Consensus. 0.12
1 1.00
Long Noncoding RNA H19 Mediates STAT3-Dependent Activation of Keratinocytes and Fibroblasts in Systemic Sclerosis Skin 1.00
13 2.80
Ruxolitinib for ciltacabtagene autoleucel–associated refractory diarrhea 0.02
Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia 0.04
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences the risk of acute myeloid leukemia 0.46
Understanding how a highly prevalent GRK5 polymorphism affects platelets and enhances thrombotic risk 0.05
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma 0.04
Daratumumab-bortezomib-thalidomide-dexamethasone for newly diagnosed myeloma: CASSIOPEIA minimal residual disease results 0.03
The ENHANCE-3 study: venetoclax and azacitidine plus magrolimab or placebo for untreated AML unfit for intensive therapy 0.05
Magrolimab plus azacitidine vs physician’s choice for untreated iTP53/i-mutated acute myeloid leukemia: the ENHANCE-2 study 0.09
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia 0.02
Shear-dependent platelet aggregation by ChAdOx1 nCoV-19 vaccine: a novel biophysical mechanism for arterial thrombosis 0.07
Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of iJAK2/i-mutated post-MPN AML 0.04
Matched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletion 0.92
Clinical significance of preleukemic somatic GATA1 mutations in children with Down syndrome 0.94
2 0.85
De novo and inherited variants in DDX39B cause a novel neurodevelopmental syndrome 0.10
Misdirected yet intact TREX1 exonuclease activity causes human cerebral and systemic small vessel disease 0.75
6 2.15
Clinical and molecular landscape of surgically resected early onset pancreatic cancer 1.00
Comparing multifocality to unifocal breast cancer and the relation to survival: a national cohort study 0.06
Management of incidental gallbladder cancer in a nationwide CAPBIL study 1.00
Management of gastric cancer peritoneal metastasis: International Gastric Cancer Association GCPM Working Group consensus statements 0.06
Oncological outcome after robot-assisted versus open pancreatoduodenectomy for upfront resectable cancer in the pancreatic head: a nationwide cohort analysis 0.01
Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: multicentre AXSANA cohort study 0.02
3 0.38
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity 0.03
Myeloid cell networks govern re-establishment of original immune landscapes in recurrent ovarian cancer 0.05
KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer 0.30
9 4.12
LOX Inhibition Disrupts a Collagen–Integrin–MYC Axis to Suppress Progression of Invasive Lobular Carcinoma 0.67
Nerves Stimulate Cross-talk Between Gastric Cancer and Group 3 Innate Lymphoid Cells to Enhance Immunosuppression 0.09
An Fc-Engineered Glycomodified Antibody Supports Proinflammatory Activation of Immune Effector Cells and Restricts Progression of Breast Cancer 0.82
Chemotherapy-Treated Breast Cancer Cells Activate the WNT Signaling Pathway to Enter a Diapause-Like Early Persister State. 0.13
Adaptive Therapy Exploits Fitness Deficits in Chemotherapy-Resistant Ovarian Cancer to Achieve Long-Term Tumor Control 0.97
Phenoscaping Reveals Multimodal γδ T Cell Cytotoxicity as a Strategy to Overcome Cancer Cell-Mediated Immunomodulation. 1.00
AREG and EREG Are Predictive Biomarkers of Response to EGFR Inhibition in Gastroesophageal Cancer 0.05
HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data 0.25
The C-terminal Kinase Domain-Binding and Suppression Motif Prevents Constitutive Activation of FGFR2 0.14
7 3.11
Nociceptive innervation limits tertiary lymphoid structures to promote lung cancer 0.63
Biodiversity and biogeography of the multi-kingdom cancer microbiome 0.14
Rational discovery of therapeutic PAK1 allosteric activators 0.73
EcDNA-borne structural variants drive oncogenic fusion transcript amplification 0.07
Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction 0.65
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers 0.75
Functional liver genomics identifies hepatokines promoting wasting in cancer cachexia 0.13
1 0.01
The S100A8/A9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice 0.01
1 0.03
Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia 0.03
1 0.20
A snapshot of flavin-conjugated Pt anticancer agents: Pt(iv)-to-Pt(ii) reduction revealed by X-ray fluorescence imaging and XANES 0.20
1 0.14
Timing of screening benefit for lung cancer with low-dose computed tomography 0.14
3 1.96
Multi-omic analyses reveal a differential contribution of chromatin-associated PP1 holoenzymes to mitotic exit and G1 re-establishment 0.94
Maternal CENP-C restores centromere symmetry in mammalian zygotes to ensure proper chromosome segregation 0.02
ER-phagy and proteostasis defects prime pancreatic epithelial state changes in KRAS-mediated oncogenesis 1.00
1 0.08
Occupational exposure to endocrine-disrupting chemicals and colorectal cancer risk - An analysis of four participating cohorts of the Canadian Partnership for Tomorrow’s Health study 0.08
6 2.31
Bacillus Calmette-Guérin Plus Mitomycin Versus Bacillus Calmette-Guérin Alone for Bacillus Calmette-Guérin–naïve Non–muscle-invasive Bladder Cancer: A Randomised Phase 3 Trial (ANZUP 1301) 0.04
Primary Noncontrast Magnetic Resonance Imaging for Prostate Cancer Screening: A Randomized Clinical Trial (PROSA) 0.05
Exploring Factors Associated with Late Urinary Toxicity After Prostate Stereotactic Body Radiotherapy: Findings from the PACE-B Study 0.90
IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical Prostatectomy 1.00
Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study 0.10
CaboPoint: A Phase 2 Study of Second-line Cabozantinib After Checkpoint Inhibitor–based Combination Therapy in Patients with Metastatic Renal Cell Carcinoma 0.23
1 0.02
Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation 0.02
4 2.32
Modeling medulloblastoma pathogenesis and treatment in human cerebellar organoids 1.00
Embryonic stem cell factors DPPA2/4 amplify active H3K4me3–H2AK119ub chromatin domains in non-small cell lung cancer 0.07
SOX2 phosphorylation during mitosis limits genomic damage 1.00
A kinetic ruler controls mRNA poly(A) tail length 0.25
1 1.00
Gene duplication is associated with gene diversification and potential neofunctionalization in lung cancer evolution 1.00
3 1.89
Gut microbiome signatures in colorectal neoplasia: a cross-sectional study across neoplasia stages and subtypes 0.94
Large-scale multiomic analysis identifies non-coding somatic driver mutations and nominates iZFP36L2/i as a driver gene for pancreatic ductal adenocarcinoma 0.02
Research priorities for cancers of the oesophagus and stomach: recommendations from a UK and Ireland patient and healthcare professional partnership exercise 0.93
3 0.23
Long-term outcomes of atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A real-world study. 0.02
Uncovering the genetic landscape of cholangiocarcinoma and its subtypes via GWAS and integrative analyses. 0.08
Refinement of histologic subtypes and identification of biomarkers linked to unfavorable prognosis in cholangiocarcinoma: The ENSCCA registries' framework for digital twin advancement. 0.13
1 0.82
Nonsense-mediated mRNA decay inhibition reshapes the cancer immunopeptidome 0.82
1 0.50
Estrogen-Functionalized Ru(II) Polypyridyl Complexes Self-Assemble into Aggregates and Exhibit Selective Phototoxicity against Breast Cancer Cells 0.50
2 0.41
Investigating the association between anthropometry and colorectal cancer survival: a two-sample Mendelian randomization analysis 0.38
Maternal prenatal infection and childhood leukaemia: a Childhood Cancer and Leukemia International Consortium (CLIC) meta-analysis 0.03
1 0.23
Frequent Missed Opportunities for Earlier Diagnosis of Advanced-Stage Colorectal or Lung Cancer 0.23
3 0.13
Activity and Physiological Stress Within 90 Days After Minimally Invasive and Open Pancreatoduodenectomy: A Predefined Analysis of the DIPLOMA-2 Randomized Clinical Trial. 0.02
International Reference Values for Surgical Outcomes of Total Pancreatectomy 0.02
Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer 0.09
4 0.80
Cancer Diagnostic Delay Rates Associated With a Population-Based Screening Trial Evaluating a Cell-Free DNA Multicancer Early Detection Test. 0.20
Biomarker-Based Eligibility for Lung Cancer Screening: Validation of the Protein-Based INTEGRAL-Risk Model. 0.06
Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer 0.10
Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis 0.45
9 4.81
Metabolic Tracing Reveals IL-2 Driven Glutaminolysis and De Novo Pyrimidine Synthesis in Human Natural Killer Cells 0.08
Integrated analysis of the adipocyte plasma membrane proteome reveals KCC1 and PIT2 as novel insulin-responsive transporters 0.02
Lipopolysaccharide induces HIF-1α accumulation via MAPK p38-mediated mRNA stabilization and dexamethasone-sensitive protein stabilization. 1.00
The receptor tyrosine kinase ErbB2/HER2 governs CDK4 inhibitor sensitivity, timing and irreversibility of the G1/S transition 0.13
Mammalian and Bacterial Adaptors Function as Co-Disinhibitory Pairs to Activate the E3 ubiquitin ligase WWP2 1.00
Structures of human protein tyrosine phosphatase variants reveal targetable allosteric sites 0.50
Rules of engagement: Determinants of chemokine receptor activation and selectivity by CCL27 and CCL28 0.08
Conformational dynamics of the bacterial E3 ligase SspH1 1.00
The cytoplasmic domain of the pseudoprotease iRhom2 mediates distinct signaling mechanisms to control activation of the cell surface protease ADAM17 1.00
4 2.85
Assembly and phosphoregulatory mechanisms of the budding yeast outer kinetochore KMN complex 1.00
Mechanical coordination between anaphase A and B drives asymmetric chromosome segregation 0.07
Acidosis attenuates the hypoxic stabilization of HIF-1α by activating lysosomal degradation 1.00
PML mutants from arsenic-resistant patients reveal SUMO1-TOPORS and SUMO2/3-RNF4 degradation pathways 0.78
3 2.88
Is adrenal adenoma to carcinoma transformation possible?—Illustrative cases and literature review 1.00
Safety and effectiveness of rivaroxaban thromboprophylaxis in adrenocorticotropic hormone–dependent Cushing syndrome 1.00
Pathogenesis of Noonan syndrome is modulated by NOC2L, a novel interactor of LZTR1 leading to impaired p53 signalling 0.88
9 2.27
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers 0.88
Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells 1.00
Genome-wide CRISPR screen identifies a cytokine–enhancer circuit driving HIF-2α activation in renal cancer 0.06
Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma 0.09
Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization 0.02
Tissue-specific anti-tumor NK cell subsets identified in colorectal cancer liver metastases express candidate therapeutic targets 0.01
T-cell acute lymphoblastic leukemia exploits a neural proinflammatory pathway to colonize the meninges 0.10
Acetyl-CoA carboxylase-1 inhibition increases regulatory T-Cell metabolism and graft-vs-host disease treatment efficacy via mitochondrial fusion 0.09
USP10/GSK3B-mediated inhibition of PTEN drives resistance to PI3K inhibitors in breast cancer 0.03
28 5.92
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond. 0.58
First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer. 0.10
Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With BRAF V600-Mutant Solid Tumors. 0.13
Residual Absolute Volume of Blastema as a Predictor of Clinical Outcomes in Patients With Wilms Tumor: A Report From the SIOP WT 2001 Study. 0.05
Pembrolizumab With or Without Lenvatinib as First-Line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Phase III LEAP-010 Study. 0.01
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer. 0.04
Integrating Electronic Patient-Reported Outcomes and Palliative Care in Pediatric Advanced Cancer: The PediQUEST Response Multisite Randomized Controlled Trial. 0.06
Survival Outcomes With or Without Risk-Reducing Mastectomy in BRCA1 and BRCA2 Pathogenic Variant Carriers. 1.00
Pharmacokinetics and Safety of Selumetinib Granule Formulation in Children With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (SPRINKLE; phase I/II). 0.08
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study. 0.02
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study 0.59
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. 0.08
Dinutuximab Beta Added to Temozolomide-Based Chemotherapy for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON Immuno Phase II Trial. 0.51
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer. 0.05
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study. 0.07
Gemcitabine intravesical system plus cetrelimab or cetrelimab alone as neoadjuvant therapy in patients with MIBC: primary analysis and biomarker results of SunRISe-4. 0.05
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma. 0.03
First-in-Human, Phase I/II Dose Escalation and Expansion Study of Zelenectide Pevedotin in Patients With Advanced Solid Tumors: Results From Monotherapy Dose Escalation. 0.41
TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. 0.06
Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/- Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability-High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis. 0.11
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. 0.05
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors. 0.44
Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study. 0.91
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. 0.03
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. 0.12
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE). 0.21
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study. 0.03
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer. 0.11
4 1.06
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma 0.25
Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma 0.26
Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases 0.33
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 0.22
1 0.36
Profiling Human Papillomavirus Lineage-Specific Capsid Antigenicity With Geographically Diverse Natural Infection Antibodies 0.36
1 1.00
SRC kinase isoforms regulate mRNA splicing during neural development 1.00
1 0.21
TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer 0.21
4 2.62
Atomistic Insights into Anomeric and Stereochemical Effects on Glucose Transport by GLUTs 1.00
NIR-Actuated Morphodynamic 2D Nanopatches for Interface-Programmed Immunoactivation and Tumor Regression 0.14
Identification of a Highly Cooperative PROTAC Degrader Targeting GTP-Loaded KRAS(On) Alleles 0.77
The Allosteric Regulator Inositol Phosphate Dramatically Affects the Efficacy and Selectivity of Inhibitors for Different HDAC Complexes 0.71
16 4.02
The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a Sub-analysis of the APHINITY trial 0.20
Temporal Patterns and Factors Associated with Early Termination in Phase 1 Clinical Trials for Solid Tumors 0.04
Improved stage-specific survival in screen-detected breast cancer in Denmark: a cohort study 0.67
Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer 0.07
Weight trajectories throughout adulthood and prostate cancer incidence, aggressiveness, and death in 258,494 men 0.09
A smoking-related plasma protein score and smoking-related cancer risk and mortality in ARIC 0.08
NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer 0.79
Different diabetes types and pancreatic ductal adenocarcinoma: a Mendelian randomization and pathway/gene-set analysis 0.01
Optimizing oncology drug development: systematic review of 22 years of myeloma randomized controlled trials 0.07
Stratifying lung adenocarcinoma risk with multi-ancestry polygenic risk scores in East Asian never-smokers 0.05
Survival deficits in young women with breast cancer in sub-Saharan Africa: the African Breast Cancer–Disparities in Outcomes cohort 0.08
Prospective associations of diabetes with 15 cancers in 2.2 million UK and Chinese adults 0.65
Discovering plasma proteins associated with breast cancer incidence in post-menopausal women in ARIC 0.13
The nucleosome remodeling and deacetylase-SWItch/sucrose non-fermentable antagonism regulates the coordinated activation of epithelial-to-mesenchymal transition and inflammation in oral cancer 0.06
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine and durvalumab: a large real-life worldwide population 0.03
Multidisciplinary evidence-based consensus statements on salvage surgery for recurrent head and neck cancer (International Centre for Recurrent head and neck Cancer) 1.00
2 0.21
A predictor finding study found patient-reported outcomes improve the prediction of mortality of incident dialysis patients 0.13
Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy 0.08
7 2.20
A time-resolved atlas of histone modifications during mitotic entry 0.62
BRCA2-dependent maturation of nascent strands during DNA replication 0.50
RNF25 confers mRNA damage tolerance by curbing activation of the integrated stress response 0.28
Cell-surface RNA forms ternary complex with RNA-binding proteins and heparan sulfate to recruit immune receptors 0.03
A redox switch in p21-CDK feedback during G2 phase controls the proliferation-cell cycle exit decision 0.55
Condensin II activation by M18BP1 0.05
CRAMP1-dependent histone H1 biogenesis is essential for topoisomerase II inhibitor tolerance 0.18
28 10.83
Evolutionary characterization of lung cancer metastasis 0.96
Early fibrotic niches establish tumour-permissive microenvironments 0.38
Dominant clones leverage developmental epigenomic states to drive ependymoma 0.06
Thymic health and immunotherapy outcomes in patients with cancer 0.30
Homologous recombination deficiency and hemizygosity drive resistance in breast cancer 0.15
Precancerous niche remodelling dictates nascent tumour persistence 0.76
Ancestry and somatic profile indicate acral melanoma origin and prognosis 0.27
Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma 0.03
Somatic evolution following cancer treatment in normal tissue 0.98
Decay of driver mutations shapes the landscape of intestinal transformation 1.00
NSD2 targeting reverses plasticity and drug resistance in prostate cancer 0.09
MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance 0.94
Anti-progestin therapy targets hallmarks of breast cancer risk 0.86
Origins of chromosome instability unveiled by coupled imaging and genomics 0.11
Parity and lactation induce T cell mediated breast cancer protection 0.01
SPP1 is required for maintaining mesenchymal cell fate in pancreatic cancer 0.63
Functional synapses between neurons and small cell lung cancer 0.00
Fluctuating DNA methylation tracks cancer evolution at clinical scale 0.29
Mechanical confinement governs phenotypic plasticity in melanoma 0.13
Targeting G1–S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors 0.05
Cancer-induced nerve injury promotes resistance to anti-PD-1 therapy 0.03
Axonal injury is a targetable driver of glioblastoma progression 0.86
NASP modulates histone turnover to drive PARP inhibitor resistance 0.14
Respiratory viral infections awaken metastatic breast cancer cells in lungs 0.10
Neutrophils drive vascular occlusion, tumour necrosis and metastasis 0.02
The mutagenic forces shaping the genomes of lung cancer in never smokers 0.04
Spatiotemporal orchestration of mitosis by cyclin-dependent kinase 0.75
Loss of colonic fidelity enables multilineage plasticity and metastasis 0.89
3 1.76
Cancer-associated fibroblasts regulate DNA repair in pancreatic cancer through NDRG1-mediated R-loop processing 0.08
Electrophilic compound screening identifies GPX4-dependent ferroptosis as a senescence vulnerability 0.68
RPA exhaustion activates SLFN11 to eliminate cells with heightened replication stress 1.00
93 42.00
ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer 0.05
Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial 1.00
High-depth whole genome sequencing of premalignant breast lesions reveals rearrangement hotspots and personalized management opportunities 0.37
Systematic discovery of motif-based interactions of the auxiliary domains of USP family deubiquitinases 0.38
Dysfunction of a SET3-like complex underlies a family of related neurological disorders 1.00
Models for the architecture of the human inner kinetochore on centromeric α-satellite CENP-A nucleosome arrays 1.00
Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling 0.03
Cell-free DNA size deconvolution resolves nucleosomal origins and reveals tumor-associated fragmentomic alterations 1.00
NCOR2 represses MHC class I molecule expression to drive metastatic progression of breast cancer 0.07
Spatial predictors of response to chemo-immunotherapy in microsatellite stable metastatic colorectal cancer 0.03
Single cell transcriptional evolution of myeloid leukemia of Down syndrome 0.84
Genetic determinants of fatigue up to 2 years after radiotherapy in prostate cancer patients 0.26
Clonal biases dictate availability of colonic cancer driver mutations for transformation 1.00
Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer 0.44
L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial 0.03
Loss of luminal lineage drives resistance to next-generation ERα antagonists in pretreated ER HER2 locally-advanced or metastatic breast cancer 0.05
Clinicopathologic and molecular predictors of survival in -deficient tubo-ovarian high-grade serous carcinoma 0.10
Lymphodepleting preconditioning impairs host antitumor immunity induced by adoptive T cell therapy in mouse models 0.06
Structural basis for pH-responsive amino acid transport via SLC7A4. 1.00
Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study 0.11
Structural basis for prostaglandin and drug transport via SLCO2A1 0.64
Multimodal imaging reveals a lysosomal drug reservoir that drives heterogeneous distribution of PARP inhibitors 0.93
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING 0.83
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors 1.00
A large-scale genome-wide association meta-analysis for nevus count provides direct insights into the genetics of melanoma 0.13
USP7 deubiquitinase stabilizes FAN1 to support DNA crosslink repair and suppress CAG repeat expansion 0.15
Necroptosis in both tumour and stromal compartments determines responsiveness to immunogenic cell death-based immunotherapy 0.94
Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas 0.63
Rank signaling drives basal cell-lineage infidelity leading to mammary tumorigenesis 0.10
R-loop editing by DNA cytosine deaminase APOBEC3B modulates the activity of oestrogen receptor enhancers 0.64
Amino acid and viral binding by the high-affinity Cationic Amino acid Transporter 1 (CAT1) from Mus musculus 1.00
Structure and mechanism of the HECT ligase HECTD3 1.00
Phytic acid (InsP6) activates HDAC3 epigenetic axis to maintain intestinal barrier function 0.08
Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma 1.00
Succinate receptor 1 restricts hematopoiesis and prevents acute myeloid leukemia progression 0.09
Splice isoform-perturbation coupled to single cell transcriptome profiling reveals functions of microexons in neurogenesis and autism-linked pathways 0.19
Olutasidenib in recurrent/relapsed locally advanced or metastatic -mutated chondrosarcoma: phase 1b/2 trial 0.18
The functional landscape of alternative splicing in hematopoietic lineage commitment 0.04
Structural basis of CSN-mediated SCF deneddylation 1.00
Structures of nucleotide-bound human telomerase at several steps of its telomeric DNA repeat addition cycle 0.67
Targeting the UFL1-AKT cascade suppresses triple-negative breast cancer progression 0.10
SOX2 confers tumour permissiveness in a specific skin progenitor population 1.00
WRN structural flexibility showcased through fragment-based lead discovery of inhibitors 0.04
Clonal evolution and transcriptional plasticity shape metastatic dissemination routes in prostate cancer 0.06
Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy 1.00
The molecular cartography of malignant and benign sebaceous tumours 0.59
Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer 0.03
Cancer stage at diagnosis by duration of pre-existing chronic analgesic use and anxiety or depression 0.83
Inhibiting translation elongation by reducing eIF5A activity induces feedback inhibition of initiation, limiting tumour cell proliferation 1.00
A recurrent pathogenic truncating variant reveals a role for BRCA2-PCAF complex in modulating NF-κB-driven transcription 0.10
ANKLE1 processes chromatin bridges by cleaving mechanically stressed DNA 0.18
Hologenomic analysis of rectal mucus sampling for detection of adenomatous polyps and colorectal cancer 0.97
Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis 0.11
Multimodal AI and tumour microenvironment integration predicts metastasis in cutaneous melanoma 0.67
Self-driven electrical triggering system activates tunneling nanotube highways to enhance drug delivery in bladder cancer therapy 0.08
RAF inhibitors activate the integrated stress response by direct activation of GCN2 0.79
A non-canonical lymphoblast in refractory childhood T-cell leukaemia 0.69
Pathogenic variants in cause an X-linked neurodevelopmental disorder modulated by NURF complex composition 0.03
BRCA2 deficiency and replication stress drive APOBEC3-Mediated genomic instability 0.10
Tumor-targeted top1 inhibitor delivery with optimized parp inhibition in advanced solid tumors: a phase i trial of gapped scheduling 0.15
HIFα isoform specific activities drive cell-type specificity of VHL-associated oncogenesis 1.00
WEE1 inhibitors synergise with mRNA translation defects via activation of the kinase GCN2 0.60
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer 0.64
The Hippo terminal effector YAP boosts enterovirus replication in type 1 diabetes 0.07
Pathogenic variants reveal candidate genes for prostate cancer germline testing for men of African ancestry 0.16
Biomimetic organo-hydrogels reveal the adipose tissue local mechanical anisotropy regulates ovarian cancer invasion 0.46
Poziotinib for EGFR exon 20-insertion NSCLC: Clinical efficacy of the phase 2 ZENITH trial and differential impact of EGFR exon 20 insertion location on sensitivity 0.12
PBK/TOPK mediates Ikaros, Aiolos and CTCF displacement from mitotic chromosomes and alters chromatin accessibility at selected C2H2-zinc finger protein binding sites 1.00
RBM39 degrader invigorates innate immunity to eradicate neuroblastoma despite cancer cell plasticity 0.06
Deep indel mutagenesis reveals the regulatory and modulatory architecture of alternative exon splicing 0.14
A comparative analysis of heterogeneity in lung cancer screening effectiveness in two randomised controlled trials 0.10
Splicing QTL mapping in stimulated macrophages associates low-usage splice junctions with immune-mediated disease risk 0.97
The balance between B55α and Greatwall expression levels predicts sensitivity to Greatwall inhibition in cancer cells 0.94
Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with rearrangement 0.04
Centromere protection requires strict mitotic inactivation of the Bloom syndrome helicase complex 1.00
Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma 0.03
Chromatin retained lncRNA integrates ABA and DOG1 signalling pathways to enhance Arabidopsis seeds dormancy 0.08
Cell free RNA detection of pancreatic cancer in pre diagnostic high risk and symptomatic patients 0.05
Functional avidity of anti-B7H3 CAR-T constructs predicts antigen density thresholds for triggering effector function 0.58
Tumor control and immune activation through palliative irradiation and ATR inhibition, PATRIOT Part C: a phase Ib trial 1.00
A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas 0.05
The oncolytic adenovirus Ad-TD-nsIL12 in primary or progressive pediatric IDH wild-type diffuse intrinsic pontine glioma results of two phase I clinical trials 0.20
Large-scale RNA-Seq mining reveals ciclopirox olamine induces TDP-43 cryptic exons 0.13
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial 0.94
The invasion phenotypes of glioblastoma depend on plastic and reprogrammable cell states 0.11
The Helicobacter pylori AI-clinician harnesses artificial intelligence to personalise H. pylori treatment recommendations 0.13
Immunodiagnostic plasma amino acid residue biomarkers detect cancer early and predict treatment response 0.19
Identification of RNF114 as ADPr-Ub reader through non-hydrolysable ubiquitinated ADP-ribose 0.53
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models 1.00
Cx43 enhances response to BRAF/MEK inhibitors by reducing DNA repair capacity 0.14
Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial 0.01
Structure of a transcribing Pol II-DSIF-SPT6-U1 snRNP complex 0.44
A heterozygous CEBPA mutation disrupting the bZIP domain in a RUNX1 and SRSF2 mutational background causes MDS disease progression 0.50
17 6.03
Age distinguishes selection from causation in cancer genomes 0.20
Transposable elements shape stemness in normal and leukemic hematopoiesis 0.11
Biallelic variants in the noncoding RNA gene RNU4-2 cause a recessive neurodevelopmental syndrome with distinct white matter changes 0.18
Systematic analysis of snRNA genes reveals frequent variants in dominant and recessive developmental and epileptic encephalopathies 0.00
Biallelic variants in cause the most prevalent known recessive neurodevelopmental disorder 0.16
A repeat expansion in is a major risk factor for atypical frontotemporal lobar degeneration with ubiquitin-positive inclusions 0.07
Comprehensive repertoire of the chromosomal alteration and mutational signatures across 16 cancer types 0.80
Global multi-ancestry genome-wide analyses identify genes and biological pathways associated with thyroid cancer and benign thyroid diseases 0.14
Childhood brain tumors instruct cranial hematopoiesis and immunotolerance 0.80
Improved polygenic risk prediction models for breast cancer subtypes in women of African ancestry 0.02
De novo and inherited dominant variants in U4 and U6 snRNA genes cause retinitis pigmentosa 0.09
Functionally dominant hotspot mutations of mitochondrial ribosomal RNA genes in cancer 0.43
Transcription factor switching drives subtype-specific pancreatic cancer 0.75
Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis 0.71
Clonal evolution of hematopoietic stem cells after autologous stem cell transplantation 0.05
The long-term effects of chemotherapy on normal blood cells 0.90
Chromothripsis-associated chromosome 21 amplification orchestrates transformation to blast-phase MPN through targetable overexpression of DYRK1A 0.63
2 0.88
Fine-tuning BACH2 dosage balances stemness and effector function to enhance antitumor T cell therapy 0.76
PARP inhibition generates enhanced CD8+ central memory T cells by transcriptional and metabolic reprogramming 0.12
16 4.00
Targeted therapies plus radiotherapy for diffuse intrinsic pontine glioma: the randomized phase 2 BIOMEDE trial 0.13
Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial 0.15
Enhanced dynamic risk stratification of smoldering multiple myeloma 0.06
AI-based chest X-ray prioritization in the lung cancer diagnostic pathway: the LungIMPACT randomized controlled trial 1.00
Implementation of the NHS England Lung Cancer Screening Programme over 5 years 1.00
Colonoscopy and fecal immunochemical testing versus usual care in diagnostic colorectal cancer screening: the SCREESCO randomized controlled trial 0.23
Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial 0.04
Time-of-day immunochemotherapy in nonsmall cell lung cancer: a randomized phase 3 trial 0.01
Adjuvant nivolumab and relatlimab in stage III/IV melanoma: the randomized phase 3 RELATIVITY-098 trial 0.04
Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial 0.04
Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial 0.04
Neoadjuvant PD-1 and LAG-3-targeting bispecific antibody and other immune checkpoint inhibitor combinations in resectable melanoma: the randomized phase 1b/2 Morpheus-Melanoma trial 0.04
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial 0.06
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial 0.08
Precemtabart tocentecan, an anti-CEACAM5 antibody–drug conjugate, in metastatic colorectal cancer: a phase 1 trial 0.08
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial 1.00
2 0.26
TDP-43 loss induces cryptic polyadenylation in ALS/FTD 0.23
Brain tumors induce widespread disruption of calvarial bone and alteration of skull marrow immune landscape 0.04
3 1.38
A proteome-wide dependency map of protein interaction motifs 0.04
UBA6 specificity for ubiquitin E2 conjugating enzymes reveals a priority mechanism of BIRC6 0.83
Heterochromatin boundaries maintain centromere position, size and number 0.50
6 3.19
Lactate and histone H3K18 lactylation are associated with metabolic control of gene expression in the retina 0.04
Histone lactylation: A new epigenetic mark in the malaria parasite Plasmodium 1.00
The syntenic long non-coding RNA DANCR is an essential regulator of zebrafish development and a human melanoma oncogene 0.89
E-cadherin endocytosis promotes non-canonical EGFR:STAT signalling to induce cell death and inhibit heterochromatinisation. 1.00
Systematically identification of survival-associated eQTLs in a Japanese kidney cancer cohort 0.10
Cell cycle dependent methylation of Dam1 contributes to kinetochore integrity and faithful chromosome segregation. 0.17
1 0.23
Systematic assessment of obesity-related risk factors in renal cancer etiology: A longitudinal risk and mendelian randomization analysis. 0.23
12 3.46
Structural and dynamic basis of indirect apoptosis inhibition by Bcl-xL: A case study with Bid 0.07
Unveiling the developmental and tumor-suppressive roles of the p53 variant p53psi 0.08
HES1 oscillations are required for cell cycle reentry in oestrogen receptor–positive breast cancer cells 1.00
Exercise suppresses DEAF1 to normalize mTORC1 activity and reverse muscle aging 0.10
CAR-SPLASH identifies nascent pre-mRNA structures implicated in kinetic coupling and alternative splicing 0.33
A TGF-βR/IL-2R immunomodulatory fusion protein transforms immunosuppression into T cell activation to enhance adoptive T cell therapy 0.08
G-quadruplexes as a source of vulnerability in BRCA2-deficient granule cell progenitors and medulloblastoma 0.04
TRIM24 as a therapeutic target in endocrine treatment–resistant breast cancer 0.13
Inactivation of PI3K-C2α deregulates cell death pathways and sensitizes to endotoxic shock 0.80
The oncogene SLC35F2 is a high-specificity transporter for the micronutrients queuine and queuosine 0.11
Single Antisense Oligonucleotides Correct Diverse Splicing Mutations in Hotspot Exons 0.11
CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor–driven proteome through PARP7 activity 0.61
3 0.37
Cross-National Radiomics Validation Using Mammography to Predict Occult Invasion in Ductal Carcinoma in Situ. 0.24
Tumor Involvement of the Nipple at Preoperative Contrast-enhanced Mammography: A Multicenter Diagnostic Accuracy Study. 0.07
Histopathologic Yields and Concordance of In-Bore MRI-targeted Biopsy for Prostate Cancer Diagnosis. 0.07
7 2.66
Cryo–electron microscopy structure of the budding yeast telomerase holoenzyme 0.43
Chromothripsis and ecDNA initiated by N4BP2 nuclease fragmentation of cytoplasm-exposed chromosomes 0.11
A non-enzymatic role of Nudix hydrolase 5 in repressing purine de novo synthesis 0.14
Covalent inhibitors of the PI3Kα RAS binding domain impair tumor growth driven by RAS and HER2 0.14
Architecture of the UBR4 complex, a giant E4 ligase central to eukaryotic protein quality control 0.11
Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA 0.95
Cryo-EM structure of human telomerase dimer reveals H/ACA RNP-mediated dimerization 0.79
16 6.43
Multiregional profiling reveals THBS1-SPP1 monocyte-macrophage axis drives immunosuppression and outcome in colorectal liver metastases 1.00
P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML 0.22
PARP4 ADP-ribosylates PIDD1 to complete a phospho/SUMO/PAR-ylation cascade that orchestrates PIDDosome assembly 0.17
Chromosomal instability shapes the tumor microenvironment of esophageal adenocarcinoma via a cGAS–chemokine–myeloid axis 0.64
Intratumoral Parvimonas micra promotes esophageal squamous cell carcinoma via p-cresol–induced Treg differentiation 0.01
Lifecourse genome-wide association study meta-analysis refines the critical life stages for adiposity’s influence on breast cancer risk 0.54
Steroid-dependent metabolic rewiring reveals novel therapeutic and imaging approaches for glioblastoma 0.63
Aberrant methylation limits antitumoral inflammation in lung adenocarcinoma by restricting RIPK3 expression 0.05
Synergistic intragenic epigenetic deregulation by IDH2 and SRSF2 mutations causes mis-splicing of key transcriptional regulators 0.11
Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation 0.72
Glial-to-mesenchymal transition of tumor Schwann cells drives the genetic burden in MPNSTs from neurofibromatosis type 1 mouse model 0.08
Mapping the genetic landscape of iron metabolism uncovers the SETD2 methyltransferase as a modulator of iron flux 1.00
Distinctive molecular features of radiation-induced thyroid cancers 0.05
Diverse oncogenes use common mechanisms to drive growth of major forms of human cancer 0.23
M6A-dependent RNA condensation underlies FUS autoregulation and can be harnessed for ALS therapy development 0.93
UFMylation maintains tumor suppressor pVHL stability by activating the deubiquitinase BAP1 0.06
5 1.08
A long-term image-derived AI-based risk model for primary prevention of breast cancer in individuals at high risk 0.07
uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target 0.01
Site-specific methylation of SRSF2P95H by SETD2 inhibits MDSC-mediated proinflammatory niche formation in mouse models of myelodysplastic syndrome 0.03
The landscape of microbial associations in human cancer 0.89
A genome-wide in vivo CRISPR activation screen identifies BACE1 as a therapeutic vulnerability of lung cancer brain metastasis 0.08
2 2.00
Prostate specific antigen retesting intervals and trends in England: population based cohort study 1.00
Second cancers in 475 000 women with early invasive breast cancer diagnosed in England during 1993-2016: population based observational cohort study 1.00
12 5.13
NGFR induces melanoma invasion and immunotherapy resistance through myosin light chain 2 modulation 0.10
Global analysis of cancer cell responses to USP9X inhibition 0.04
Microtubule end stabilisation by cooperative oligomers of Ska and Ndc80 complexes 0.75
Pervasive phenotypic effects of FBXO42 are promoted by regulation of PP4 phosphatase 0.75
The transaminase-ω-amidase pathway senses oxidative stress to control glutamine metabolism and α-ketoglutarate levels in endothelial cells 0.00
Concurrence of mutations modulates oncogenesis in glioneuronal tumors 0.03
Nucleosome interaction of the CPC secures centromeric chromatin integrity and chromosome segregation fidelity 0.60
Resistance to CDK7 inhibitors directed by acquired mutation of a conserved residue in cancer cells. 0.75
Parp7 generates an ADP-ribosyl degron that controls negative feedback of androgen signaling. 0.23
Targeting SUMO2 reverses aberrant epigenetic rewiring driven by SS18::SSX fusion oncoproteins and impairs sarcomagenesis. 0.08
WIP1 mutations suppress DNA damage triggered bypass of the mitotic timer. 1.00
CHD8 interacts with BCL11A to induce oncogenic transcription in triple negative breast cancer 0.79
14 3.41
Long-term effects of colonoscopy screening on colorectal cancer incidence and mortality: a multicountry, population-based randomised controlled trial 0.09
Progress towards the WHO Global Initiative for Childhood Cancer target of 60% 5-year survival for all childhood cancers combined, 1990–2019 (CONCORD-4): a Cancer Survival Index derived for 68 countries by analysis of individual records for 613 021 children from 307 population-based cancer registries 0.50
Proton beam therapy for oropharyngeal cancer (TORPEdO): a phase 3, randomised controlled trial 1.00
Hormone therapy use and duration with postoperative radiotherapy for recurrent prostate cancer: an individual patient data meta-analysis 0.06
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study 0.03
Socioeconomic inequalities in cancer survival and access to health care among children and adolescents in China, 2018–24: a prospective nationwide cohort study 0.03
Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories 0.20
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial 0.05
Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial 0.12
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial 0.05
Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial 1.00
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial 0.19
Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial 0.04
1 1.00
Trajectories of type 2 diabetes and cancer in 330 000 individuals with prediabetes: 20-year observational study in England 1.00
1 0.07
Breast cancer overall survival, annual risks of death, and survival gap apportionment in sub-Saharan Africa (ABC-DO): 7-year follow-up of a prospective cohort study 0.07
24 6.96
Real-world heart and lung doses from 30 000 National Health Service radiotherapy treatment plans in England: a national audit of breast radiotherapy practice 1.00
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials 0.07
Bayesian sequential learning for prognostication in extremity soft tissue sarcoma (BayeSarc): a retrospective, multicentre cohort study 0.11
Interpretation of constitutional cancer predisposition gene variants in 14 765 individuals in the 100 000 Genomes Project cancer arm: a retrospective cohort analysis 1.00
Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study 0.04
Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration 0.04
Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial 0.03
First-line tiragolumab plus atezolizumab and chemotherapy in patients with previously untreated, locally advanced unresectable or metastatic oesophageal cancer (MORPHEUS-EC): a randomised, open-label, phase 1b/2 trial 0.17
Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study 0.01
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial 0.10
Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial 0.04
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial 0.03
Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial 0.04
Clinical potential of whole-genome data linked to mortality statistics in patients with breast cancer in the UK: a retrospective analysis 0.99
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): 10-year clinical outcomes and post-hoc analysis by molecular classification from a randomised phase 3 trial 0.17
TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial 0.05
Health-related quality of life in patients with KRAS G12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial 0.05
Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis 0.13
Belantamab mafodotin plus bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): updated overall survival analysis from a global, randomised, open-label, phase 3 trial 0.10
Derivation and validation of the AJCC9V pathological stage classification for HPV-positive oropharyngeal carcinoma: a multicentre registry analysis 0.13
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol 0.96
Hormone therapy use and young-onset breast cancer: a pooled analysis of prospective cohorts included in the Premenopausal Breast Cancer Collaborative Group 0.16
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial 0.92
Partial-breast radiotherapy after breast conservation surgery for women with early breast cancer (UK IMPORT LOW): 10-year outcomes from a multicentre, open-label, randomised, controlled, phase 3, non-inferiority trial 0.62
22 3.00
Teclistamab in Multiple Myeloma with One to Three Previous Lines of Therapy 0.04
First-Line Zongertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.04
A Phase 3 Trial of Brepocitinib in Dermatomyositis 0.02
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer 0.05
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma 0.07
Universal Base-Edited CAR7 T Cells for T-Cell Acute Lymphoblastic Leukemia 1.00
Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer 0.84
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer 0.05
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer 0.05
Nivolumab for Resected Stage III or IV Melanoma at 9 Years 0.07
Sevabertinib in Advanced HER2-Mutant Non–Small-Cell Lung Cancer 0.03
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC 0.14
Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC 0.02
Multidose Ondansetron after Emergency Visits in Children with Gastroenteritis 0.04
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer 0.03
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer 0.04
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy 0.04
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer 0.08
Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer 0.04
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer 0.04
Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer 0.08
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast Cancer 0.20
5 4.94
Impact of a national mesothelioma network on outcomes including survival 1.00
Upstaging of screen-detected lung cancers during diagnostic assessment 0.98
Time to next procedure in patients with malignant pleural effusion undergoing aspiration: derivation and initial validation of the RED score 1.00
Frailty, comorbidity and survival comparisons between populations eligible for screening according to risk factor versus risk score criteria: results from the Yorkshire Lung Screening Trial 0.96
Performance of volume and diameter thresholds in malignancy prediction of solid nodules in lung cancer screening 1.00

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.